Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Strive Asset Management LLC

Strive Asset Management LLC reduced its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 13.4% in the first quarter, HoldingsChannel.com reports. The fund owned 509 shares of the biopharmaceutical company’s stock after selling 79 shares during the quarter. Strive Asset Management LLC’s holdings in Regeneron Pharmaceuticals were worth $323,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. Integrity Alliance LLC. bought a new stake in Regeneron Pharmaceuticals during the first quarter worth approximately $579,000. Anchor Investment Management LLC raised its holdings in Regeneron Pharmaceuticals by 19.0% during the first quarter. Anchor Investment Management LLC now owns 1,196 shares of the biopharmaceutical company’s stock worth $759,000 after purchasing an additional 191 shares in the last quarter. Glenview Trust co raised its holdings in Regeneron Pharmaceuticals by 14.5% during the first quarter. Glenview Trust co now owns 3,515 shares of the biopharmaceutical company’s stock worth $2,229,000 after purchasing an additional 444 shares in the last quarter. Ilmarinen Mutual Pension Insurance Co raised its holdings in Regeneron Pharmaceuticals by 30.7% during the first quarter. Ilmarinen Mutual Pension Insurance Co now owns 14,900 shares of the biopharmaceutical company’s stock worth $9,450,000 after purchasing an additional 3,500 shares in the last quarter. Finally, Plato Investment Management Ltd raised its holdings in Regeneron Pharmaceuticals by 41.9% during the first quarter. Plato Investment Management Ltd now owns 3,777 shares of the biopharmaceutical company’s stock worth $2,421,000 after purchasing an additional 1,116 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN opened at $556.53 on Wednesday. The stock has a market capitalization of $58.99 billion, a P/E ratio of 14.03, a P/E/G ratio of 1.87 and a beta of 0.35. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,170.58. The business’s fifty day moving average is $563.69 and its two-hundred day moving average is $581.96. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The company had revenue of $3.68 billion for the quarter, compared to analysts’ expectations of $3.30 billion. During the same quarter in the prior year, the company earned $11.56 earnings per share. The firm’s revenue was up 3.6% on a year-over-year basis. On average, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.6%. The ex-dividend date was Monday, August 18th. Regeneron Pharmaceuticals’s payout ratio is presently 8.87%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Sanford C. Bernstein boosted their target price on Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the stock an “outperform” rating in a report on Wednesday, August 27th. Morgan Stanley reissued an “overweight” rating and set a $761.00 target price (up previously from $754.00) on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. UBS Group reissued a “neutral” rating on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Wells Fargo & Company cut Regeneron Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $580.00 price target on the stock. in a report on Friday, August 1st. Finally, JPMorgan Chase & Co. dropped their price target on Regeneron Pharmaceuticals from $950.00 to $800.00 and set an “overweight” rating on the stock in a report on Monday, June 9th. Three investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, six have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $817.67.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.